Quote | Gracell Biotechnologies Inc. (NASDAQ:GRCL)
Last: | $10.25 |
---|---|
Change Percent: | -0.1% |
Open: | $10.26 |
Close: | $10.25 |
High: | $10.28 |
Low: | $10.17 |
Volume: | 6,417,173 |
Last Trade Date Time: | 02/21/2024 03:00:00 am |
News | Gracell Biotechnologies Inc. (NASDAQ:GRCL)
Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...
2024-02-21 11:51:31 ET Summary AstraZeneca PLC has announced a deal to acquire Gracell Biotechnologies Inc., a Chinese company focused on developing cell therapies for cancer and autoimmune diseases. The terms of the acquisition include a cash payment of $10 per Gracell ADR and a ...
Message Board Posts | Gracell Biotechnologies Inc. (NASDAQ:GRCL)
Subject | By | Source | When |
---|---|---|---|
$GRCL NEWS https://finance.yahoo.com/news/gracell-biotechnologies-announces-fda-c | TheFinalCD | investorshub | 02/03/2023 1:00:14 PM |
https://ih.advfn.com/stock-market/NASDAQ/gracell-biotechnologies-GRCL/stock-news/89736033/gracell-bi | north40000 | investorshub | 12/08/2022 8:25:58 PM |
GRCL and other biotechs are starting to turn | conix | investorshub | 04/04/2022 3:17:08 PM |
Gracell Gets FDA Orphan Designation for GC012F in | crudeoil24 | investorshub | 11/19/2021 11:52:03 AM |
Gracell Biotechnologies Inc is a China-based clinical-stage biopharmaceutical | crudeoil24 | investorshub | 11/19/2021 11:50:54 AM |
News, Short Squeeze, Breakout and More Instantly...
Gracell Biotechnologies Inc. Company Name:
GRCL Stock Symbol:
NASDAQ Market:
Gracell Biotechnologies Inc. Website:
Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell ...
Gracell Biotechnologies Inc. (NASDAQ: GRCL) is the focus of IBN's latest stock spotlight. The company's shares have moved -0.49% on the day to $10.19. Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of ...